Somnomed Limited · ASX:SOM
Somnomed — Investor Presentation (September 2009)
19 slides from Somnomed's investor presentation, Sep 7, 2009
Slide 1: Growth and Profitability
For personal use only Growth and Profitability Investor Presentation September 2009 This presentation contains forward-looking statements that involve risks and uncertainties. These forward-looking statements are not guarantees of SomnoMed's future performance and involve a number of risks and uncer
Slide 2: SomnoMed - Dental Sleep Medicine
SomnoMed® - Dental Sleep Medicine For personal use only Improving Health and Quality of Life Through Better Breathing and Sleep. Global leadership in Dental Sleep Medicine offering evidence based, non-invasive, innovative solutions advancing the treatment of sleep- disordered breathing. Investor Pre
Slide 3: SomnoMed's Growth Story
SomnoMed’s Growth Story For personal use only Listed on the Start up and FDA approval, Restructure, SomnoDent® MAS Significant growth Australian Stock infrastructure Expansion into New Management, positioned as a in North America Exchange development US market CE approval, leading dental/ and Europe
Slide 4: SomnoMed - A Global Player
SomnoMed® - A Global Player For personal use only Investor Presentation September 2009 4
Slide 5: Sleep Disordered Breathing (SDB) - A 21st Century Epidemic
Sleep Disordered Breathing (SDB)- A 21st Century Epidemic For personal use only • Excessive daytime sleepiness • Grogginess and morning headaches • Loud or disruptive snoring • Obesity • Gasping or choking during sleeping 5
Slide 6: Treating Sleep-Disordered Breathing
Treating Sleep-Disordered Breathing For personal use only Source: Company data and estimates Investor Presentation September 2009 6
Slide 7: Traditional SDB Treatment Options
Traditional SDB Treatment Options For personal use only Irreversible Success rate 50% Painful, slow recovery Very expensive Success rate *100% Compliance 50% Expensive *Success rate defined as reduction of AHI Investor Presentation September 2009 7 (apnea hypopnea index) to less than 5 /hour
Slide 8: SomnoDent - Third Generation Treatment Option
SomnoDent® - Third Generation Treatment Option For personal use only Success rate *50-70% Comfortable Compliance >90% MAS GOLD STANDARD Least expensive PATENTED – CLINICALLY PROVEN – COMPLIANT OSA TREATMENT *Success rate defined as reduction of AHI Investor Presentation September 2009 8 (apnea hypop
Slide 9: Highlights in FY 08/09
Highlights in FY 08/09 For personal use only • Sales revenue increased by 112% to A$ 7.7 million • Unit sales increased by 74% to 12,254 • Full year group operational profitability before Corporate/R&D • EBITDA loss for full year reduced by 35.4% to A$ 1.5 million • First cash flow positive quarter
Slide 10: Objectives and Strategic Tasks FY 09/10
Objectives and Strategic Tasks FY 09/10 For personal use only • Sales revenue > A$ 10 million • Unit sales >18,000 • Full year positive EBITDA • Expansion of the SomnoMed Dental Network > 2,300 • Development of the SomnoMed Medical Network • Foundation of SomnoMed Academy Investor Presentation Septe
Slide 11: North America-Europe-APAC Drive Volume Growth
North America-Europe-APAC Drive Volume Growth For personal use only Unit contribution per region est. FY 09/10 6000 TOTAL 5000 CAGR Units 64% 4000 3000 2000 14% 17% USA 1000 AUS EU 0 69% 7 8 9 0 6 6 7 7 8 8 9 9 07 08 09 10 -0 -0 -0 -1 -0 0 -0 0 -0 -0 -0 -0 n- n- n- n- c- c- ar ar ar ar ep ep ep ep e
Slide 12: Group Operating Profit before Corporate and R&D
Group Operating Profit before Corporate and R&D For personal use only $3,000 $2,000 $2,000 $1,000 $A '000 $20 $0 -$1,000 -$934 -$1,589 -$2,000 -$3,000 -$3,262 -$4,000 FY 05/06 FY 06/07 FY 07/08 FY 08/09 Est. FY 2010 Investor Presentation September 2009 12
Slide 13: Strong Growth in Revenue and Gross Margin
Strong Growth in Revenue and Gross Margin For personal use only Revenues 18,000 CAGR Revenue 54% Gross Margins 16,000 GM improvement from 45% to est. 57% in 2010 14,000 12,000 $10,000 10,000 $A'000 8,000 $7,737 6,000 4,000 $3,658 $5,700 2,000 $2,273 $4,059 $1,786 $1,957 $801 $1,002 0 FY 05/06 FY 06/
Slide 14: Sleep Disordered Breathing (SDB) Affects Millions
Sleep Disordered Breathing (SDB) Affects Millions For personal use only Investor Presentation September 2009 14
Slide 15: Continued Growth in SDB Treatment Market
Continued Growth in SDB Treatment Market For personal use only 6,000,000 OAT CPAP 5,000,000 20% • 15 – 20% growth rate p.a. 4,000,000 • > 60% of diagnosed # units 3,000,000 patients are untreated • Shift expected to a more 2,000,000 80% compliant Oral Appliance <5% Therapy 1,000,000 >95% 0 2008 2010
Slide 16: The SomnoDent MAS Growth Opportunity
The SomnoDent MAS Growth Opportunity For personal use only Only 10% of physicians inquire about sleep apnea related symptoms. Reuveni, et al (2004) Only 10% of adults with SDB have been diagnosed. Young, et al (1997) Approx. 50% of OSA patients recommended for CPAP either reject this option or disco
Slide 17: SomnoMed's unique Advantage
SomnoMed’s unique Advantage For personal use only SomnoMed ® - Global Leadership in Dental Sleep Medicine SomnoMed Dental SomnoMed Medical SomnoMed Academy Network Network Product Innovation Clinical evidence Dental & Medical Clinical competence Patented Education Practice development Efficacy Advis
Slide 18: Continued Growth expected
Continued Growth expected For personal use only y nit tr u po op 40,000 th row g ed 35,000 rat le cce 30,000 A 25,000 # units 20,000 36,000 15,000 25,000 10,000 18,000 12,000 5,000 7,000 2,500 3,500 1,500 0 FY 04/05 FY 05/06 FY 06/07 FY 07/08 FY 08/09 Est. FY 09/10 Est. FY10/11 Est. FY11/12 Source:
Slide 19: Contacts
For personal use only Contacts: Chairman Dr Peter Neustadt Chief Executive Officer Mr Ralf Barschow Address Telephone Level 3, +61 (0)2 9467 0400 20 Clarke Street Crows Nest NSW 2065 Website Australia www.somnomed.com.au Investor Presentation September 2009 19